Siamak Daneshmand, MD

Professor of Urology (Clinical Scholar)

Director of Clinical Research

Image of Siamak Daneshmand, MD
Is this your profile? Click to edit

Overview

BIOGRAPHY
Dr. Sia Daneshmand is currently Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as director of urologic oncology, as well as the urologic oncology (SUO) fellowship director at the University of Southern California (USC) in Los Angeles. His main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer. He is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer and is one of the highest volume surgeons for this disease in the country. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy and post-chemo RPLND, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the AUA Guidelines panel for non-muscle invasive bladder cancer, as well as the AUA Guidelines panel for Testicular cancer. He currently serves as the chair of bladder section of the SUO Clinical Trials Consortium (SUO-CTC), is on the scientific steering committee of several bladder cancer clinical trials and has led over a dozen clinical trials in bladder cancer and a pivotal investigator initiated mutli-institutional trial in testicular cancer (SEMS). He is current secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 13 consecutive years. He has been a career leader in academic investigations in bladder cancer and germ cell tumors and was recently appointed as the chair of the SWOG local bladder committee. He has been a visiting professor at more than 25 institutions around the world. He has presented over 500 abstracts at scientific meetings and has authored or co-authored over 400 peer-reviewed articles, reviews, and book chapters.

Publications

  • Performance of the EORTC and CUETO risk prediction models in contemporary patients undergoing transurethral resection of bladder tumor with blue light cystoscopy. Urol Oncol. 2026 Sep 15.. View in PubMed
  • Evaluation of Urinary Circulating Tumor DNA to Detect Minimal Residual Disease in Patients with High-Risk Non-Muscle Invasive Bladder Cancer. medRxiv. 2026 Sep 11.. View in PubMed
  • Evaluation, etiology, and management of gross hematuria following radical cystectomy and orthotopic neobladder. Urol Oncol. 2026 Oct; 44(10):617-623.. View in PubMed
  • Parastomal Hernia Following Ileal Conduit Diversion: Prevention and Management. Urol Clin North Am. 2026 Nov; 53(4):583-592.. View in PubMed
  • Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial. JAMA Netw Open. 2026 07 01; 9(7):e2623622.. View in PubMed
  • Cystectomy Remains Standard of Care Following Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer. Eur Urol. 2026 Jun 17.. View in PubMed
  • How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e516212.. View in PubMed
  • Active surveillance in low-grade NMIBC – results of an international two-round modified Delphi consensus. Nat Rev Urol. 2026 Apr 01.. View in PubMed
  • Tissue Penetration of Gemcitabine and Gemcitabine Phosphate Metabolites Following Gemcitabine Intravesical System Administration Versus Standard Intravesical Instillation in a Preclinical Minipig Model. Eur Urol Focus. 2026 Mar 20.. View in PubMed
  • Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2026 Jun; 89(6):500-511.. View in PubMed